MX2016012573A - Compuestos de dihidropirimidina y su aplicacion en productos farmaceuticos. - Google Patents
Compuestos de dihidropirimidina y su aplicacion en productos farmaceuticos.Info
- Publication number
- MX2016012573A MX2016012573A MX2016012573A MX2016012573A MX2016012573A MX 2016012573 A MX2016012573 A MX 2016012573A MX 2016012573 A MX2016012573 A MX 2016012573A MX 2016012573 A MX2016012573 A MX 2016012573A MX 2016012573 A MX2016012573 A MX 2016012573A
- Authority
- MX
- Mexico
- Prior art keywords
- compounds
- pharmaceuticals
- application
- dihydropyrimidine compounds
- dihydropyrimidine
- Prior art date
Links
- WCFAPJDPAPDDAQ-UHFFFAOYSA-N 1,2-dihydropyrimidine Chemical class C1NC=CC=N1 WCFAPJDPAPDDAQ-UHFFFAOYSA-N 0.000 title abstract 2
- 239000003814 drug Substances 0.000 title 1
- 150000001875 compounds Chemical class 0.000 abstract 2
- 201000010099 disease Diseases 0.000 abstract 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 2
- 150000003839 salts Chemical class 0.000 abstract 2
- 239000012453 solvate Substances 0.000 abstract 2
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
- A61K31/541—Non-condensed thiazines containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Virology (AREA)
- Engineering & Computer Science (AREA)
- Communicable Diseases (AREA)
- Molecular Biology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Oncology (AREA)
- Biotechnology (AREA)
- Gastroenterology & Hepatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201410126202 | 2014-03-28 | ||
| CN201410596489 | 2014-10-29 | ||
| PCT/CN2015/075299 WO2015144093A1 (en) | 2014-03-28 | 2015-03-27 | Dihydropyrimidine compounds and their application in pharmaceuticals |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2016012573A true MX2016012573A (es) | 2018-02-19 |
Family
ID=54160517
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2016012573A MX2016012573A (es) | 2014-03-28 | 2015-03-27 | Compuestos de dihidropirimidina y su aplicacion en productos farmaceuticos. |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US9771358B2 (enExample) |
| EP (1) | EP3122747B1 (enExample) |
| JP (1) | JP2017512789A (enExample) |
| KR (1) | KR20160133563A (enExample) |
| CN (1) | CN104945395B (enExample) |
| AU (1) | AU2015236982B2 (enExample) |
| CA (1) | CA2938050A1 (enExample) |
| MX (1) | MX2016012573A (enExample) |
| MY (1) | MY196243A (enExample) |
| RU (1) | RU2682672C2 (enExample) |
| SG (1) | SG11201605896WA (enExample) |
| WO (1) | WO2015144093A1 (enExample) |
Families Citing this family (66)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP5977837B2 (ja) | 2011-12-21 | 2016-08-24 | ノヴィラ・セラピューティクス・インコーポレイテッド | Ｂ型肝炎抗ウイルス剤 |
| SG11201501359TA (en) | 2012-08-28 | 2015-03-30 | Janssen Sciences Ireland Uc | Sulfamoyl-arylamides and the use thereof as medicaments for the treatment of hepatitis b |
| US10125094B2 (en) | 2013-02-28 | 2018-11-13 | Janssen Sciences Ireland Uc | Sulfamoyl-arylamides and the use thereof as medicaments for the treatment of hepatitis B |
| US9895349B2 (en) | 2013-04-03 | 2018-02-20 | Janssen Sciences Ireland Us | N-phenyl-carboxamide derivatives and the use thereof as medicaments for the treatment of hepatitis B |
| RS57999B1 (sr) | 2013-05-17 | 2019-01-31 | Janssen Sciences Ireland Uc | Derivati sulfamoiltiofenamida i njihova primena kao lekovi za tretman hepatitisa b |
| JO3603B1 (ar) | 2013-05-17 | 2020-07-05 | Janssen Sciences Ireland Uc | مشتقات سلفامويل بيرولاميد واستخدامها كادوية لمعالجة التهاب الكبد نوع بي |
| PT3024819T (pt) | 2013-07-25 | 2018-05-25 | Janssen Sciences Ireland Uc | Derivados da pirrolamida substituída com glioxamida e sua utilização como medicamentos para o tratamento da hepatite b |
| MX368158B (es) | 2013-10-23 | 2019-09-20 | Janssen Sciences Ireland Uc | Derivados de carboxamida y su uso como medicamentos para el tratamiento de la hepatitis b. |
| SG11201601813UA (en) | 2013-11-27 | 2016-04-28 | Sunshine Lake Pharma Co Ltd | Processes for preparing dihydropyrimidine derivatives and intermediates thereof |
| US9169212B2 (en) | 2014-01-16 | 2015-10-27 | Novira Therapeutics, Inc. | Azepane derivatives and methods of treating hepatitis B infections |
| US10392349B2 (en) | 2014-01-16 | 2019-08-27 | Novira Therapeutics, Inc. | Azepane derivatives and methods of treating hepatitis B infections |
| ES2792848T3 (es) | 2014-02-05 | 2020-11-12 | Novira Therapeutics Inc | Politerapia para el tratamiento de infecciones por VHB |
| CN110483484A (zh) | 2014-02-06 | 2019-11-22 | 爱尔兰詹森科学公司 | 氨磺酰基吡咯酰胺衍生物及其作为药物用于治疗乙型肝炎的用途 |
| JP2018510159A (ja) | 2015-03-19 | 2018-04-12 | ノヴィラ・セラピューティクス・インコーポレイテッド | アゾカン及びアゾナン誘導体及びｂ型肝炎感染症の治療法 |
| WO2016161268A1 (en) | 2015-04-01 | 2016-10-06 | Enanta Pharmaceuticals, Inc. | Hepatitis b antviral agents |
| US10738035B2 (en) | 2015-05-13 | 2020-08-11 | Enanta Pharmaceuticals, Inc. | Hepatitis B antiviral agents |
| US10875876B2 (en) | 2015-07-02 | 2020-12-29 | Janssen Sciences Ireland Uc | Cyclized sulfamoylarylamide derivatives and the use thereof as medicaments for the treatment of hepatitis B |
| WO2017011552A1 (en) * | 2015-07-13 | 2017-01-19 | Enanta Pharmaceuticals, Inc. | Hepatitis b antiviral agents |
| US10301255B2 (en) | 2015-07-22 | 2019-05-28 | Enanta Pharmaceuticals, Inc. | Hepatitis B antiviral agents |
| CA3000197A1 (en) | 2015-09-29 | 2017-04-06 | Novira Therapeutics, Inc. | Crystalline forms of a hepatitis b antiviral agent |
| US10280175B2 (en) | 2016-02-02 | 2019-05-07 | Enanta Pharmaceuticals, Inc. | Hepatitis B antiviral agents |
| MY198617A (en) | 2016-03-07 | 2023-09-11 | Enanta Pharm Inc | Hepatitis b antiviral agents |
| SG11201808949SA (en) | 2016-04-15 | 2018-11-29 | Novira Therapeutics Inc | Combinations and methods comprising a capsid assembly inhibitor |
| WO2017198201A1 (en) * | 2016-05-19 | 2017-11-23 | Sunshine Lake Pharma Co., Ltd. | Crystalline form, salt and complex of dihydropyrimidine derivative, and uses thereof in medicine |
| BR112018075465A2 (pt) | 2016-06-10 | 2019-03-19 | Enanta Pharmaceuticals, Inc. | agentes antivirais de hepatite b |
| CN107674072B (zh) * | 2016-08-01 | 2020-11-24 | 广东东阳光药业有限公司 | 二氢嘧啶衍生物及其酸加成物的制备方法 |
| US11166954B2 (en) | 2016-11-18 | 2021-11-09 | Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. | Dihydropyrimidine compound and preparation method and use thereof |
| MY194471A (en) | 2016-11-18 | 2022-11-30 | Sichuan Kelun Biotech Biopharmaceutical Co Ltd | Dihydropyrimidine compound and preparation method and use thereof |
| KR102665544B1 (ko) * | 2017-06-26 | 2024-05-14 | 선샤인 레이크 파르마 컴퍼니 리미티드 | 디하이드로피리미딘 화합물 및 약제에서의 이의 용도 |
| JP2020525490A (ja) | 2017-06-27 | 2020-08-27 | ヤンセン ファーマシューティカ エヌ．ベー． | ヘテロアリールジヒドロピリミジン誘導体及びｂ型肝炎感染を治療する方法 |
| WO2019046271A1 (en) | 2017-08-28 | 2019-03-07 | Enanta Pharmaceuticals, Inc. | ANTIVIRAL AGENTS AGAINST HEPATITIS B |
| AU2018361364B2 (en) | 2017-11-02 | 2020-11-26 | Aicuris Gmbh & Co. Kg | Novel, highly active amino-thiazole substituted indole-2-carboxamides active against the hepatitis B virus (HBV) |
| BR112020008765A2 (pt) | 2017-11-02 | 2020-10-20 | Aicuris Gmbh & Co. Kg | indol-2-carboxamidas pirazolo-piperidina substituídas altamente ativas inovadoras ativas contra o vírus da hepatite b (hbv) |
| WO2019113175A1 (en) | 2017-12-06 | 2019-06-13 | Enanta Pharmaceuticals, Inc. | Hepatitis b antiviral agents |
| TW201927789A (zh) | 2017-12-06 | 2019-07-16 | 美商因那塔製藥公司 | B型肝炎抗病毒試劑 |
| US11058678B2 (en) | 2018-01-22 | 2021-07-13 | Enanta Pharmaceuticals, Inc. | Substituted heterocycles as antiviral agents |
| AU2019235522A1 (en) | 2018-03-14 | 2020-09-03 | Janssen Sciences Ireland Unlimited Company | Capsid assembly modulator dosing regimen |
| US10729688B2 (en) | 2018-03-29 | 2020-08-04 | Enanta Pharmaceuticals, Inc. | Hepatitis B antiviral agents |
| CN108329308B (zh) * | 2018-05-16 | 2022-11-01 | 四川科伦博泰生物医药股份有限公司 | 一种二氢嘧啶类化合物的固体形式及其制备方法 |
| CN109021015B (zh) * | 2018-07-12 | 2019-12-03 | 山东大学 | 二氢嘧啶-磷酰胺类衍生物及其制备方法与应用 |
| US11053235B2 (en) | 2018-08-09 | 2021-07-06 | Janssen Sciences Ireland Unlimited Company | Substituted 1,4-dihydropyrimidines for the treatment of HBV infection or HBV-induced diseases |
| TW202024093A (zh) | 2018-09-21 | 2020-07-01 | 美商安塔製藥公司 | 作為抗病毒劑之官能化雜環 |
| KR20210098985A (ko) | 2018-11-02 | 2021-08-11 | 아이쿠리스 게엠베하 운트 코. 카게 | B형 간염 바이러스 (hbv)에 대해 활성인 신규 우레아 6,7-디히드로-4h-티아졸로[5,4-c]피리딘 |
| UY38437A (es) | 2018-11-02 | 2020-05-29 | Aicuris Gmbh & Co Kg | Nuevas urea 6,7-dihidro-4h-pirazolo[1,5-a]pirazinas activas contra el virus de la hepatitis b (hbv) |
| UY38439A (es) | 2018-11-02 | 2020-05-29 | Aicuris Gmbh & Co Kg | Novedosas urea 6,7-dihidro-4h-pirazolo[4,3-c]piridinas activas contra el virus de la hepatitis b (vhb) |
| AR116948A1 (es) | 2018-11-02 | 2021-06-30 | Aicuris Gmbh & Co Kg | Derivados de urea 6,7-dihidro-4h-pirazolo[1,5-a]pirazinas activas contra el virus de la hepatitis b (vhb) |
| AR117189A1 (es) | 2018-11-02 | 2021-07-21 | Aicuris Gmbh & Co Kg | Derivados de 6,7-dihidro-4h-pirazolo[1,5-a]pirazin indol-2-carboxamidas activos contra el virus de la hepatitis b (vhb) |
| UY38436A (es) | 2018-11-02 | 2020-05-29 | Aicuris Gmbh & Co Kg | Nuevas 6,7-dihidro-4h-pirazolo[1,5-a] pirazinindol-2-carboxamidas activas contra el virus de la hepatitis b (vhb) |
| BR112021009854A2 (pt) | 2018-11-21 | 2021-08-17 | Enanta Pharmaceuticals, Inc. | heterociclos funcionalizados como agentes antivirais |
| TW202035412A (zh) * | 2018-12-20 | 2020-10-01 | 比利時商健生藥品公司 | 雜芳基二氫嘧啶衍生物和治療ｂ型肝炎感染之方法 |
| AU2020223865A1 (en) | 2019-02-22 | 2021-07-15 | Janssen Sciences Ireland Unlimited Company | Amide derivatives useful in the treatment of HBV infection or HBV-induced diseases |
| CN113748113A (zh) | 2019-04-30 | 2021-12-03 | 艾库里斯有限及两合公司 | 具有抗乙型肝炎病毒(hbv)活性的新型吲哚嗪-2-甲酰胺类化合物 |
| MX2021013105A (es) | 2019-04-30 | 2021-11-17 | Aicuris Gmbh & Co Kg | Nuevas oxalil piperazinas activas contra el virus de la hepatitis b (vhb). |
| CN113767102A (zh) | 2019-04-30 | 2021-12-07 | 艾库里斯有限及两合公司 | 具有抗乙型肝炎病毒(hbv)活性的新的苯基和吡啶基脲类化合物 |
| CU20210088A7 (es) | 2019-04-30 | 2022-06-06 | Aicuris Gmbh & Co Kg | Compuestos derivados sustituidos de indol-2-carboxamidas activas contra el virus de la hepatitis b (vhb) |
| AR119732A1 (es) | 2019-05-06 | 2022-01-05 | Janssen Sciences Ireland Unlimited Co | Derivados de amida útiles en el tratamiento de la infección por vhb o de enfermedades inducidas por vhb |
| WO2020247444A1 (en) | 2019-06-03 | 2020-12-10 | Enanta Pharmaceuticals, Inc, | Hepatitis b antiviral agents |
| WO2020247561A1 (en) | 2019-06-04 | 2020-12-10 | Enanta Pharmaceuticals, Inc, | Hepatitis b antiviral agents |
| US11472808B2 (en) | 2019-06-04 | 2022-10-18 | Enanta Pharmaceuticals, Inc. | Substituted pyrrolo[1,2-c]pyrimidines as hepatitis B antiviral agents |
| WO2020255015A1 (en) * | 2019-06-18 | 2020-12-24 | Janssen Sciences Ireland Unlimited Company | Combination of hepatitis b virus (hbv) vaccines and dihydropyrimidine derivatives as capsid assembly modulators |
| US11738019B2 (en) | 2019-07-11 | 2023-08-29 | Enanta Pharmaceuticals, Inc. | Substituted heterocycles as antiviral agents |
| US11236108B2 (en) | 2019-09-17 | 2022-02-01 | Enanta Pharmaceuticals, Inc. | Functionalized heterocycles as antiviral agents |
| CN110615797A (zh) * | 2019-10-11 | 2019-12-27 | 李丽丽 | 用于治疗乙型肝炎的化合物及其用途 |
| US11802125B2 (en) | 2020-03-16 | 2023-10-31 | Enanta Pharmaceuticals, Inc. | Functionalized heterocyclic compounds as antiviral agents |
| MX2023007287A (es) | 2020-12-17 | 2023-07-03 | Astrazeneca Ab | N-(2-(4-cianotiazolidin-3-il)-2-oxoetil)-quinolin-4-carboxamidas. |
| WO2022166923A1 (zh) | 2021-02-05 | 2022-08-11 | 和博医药有限公司 | 苯基二氢嘧啶类化合物及其应用 |
Family Cites Families (41)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0202654A3 (en) | 1985-05-20 | 1987-12-16 | E.R. Squibb & Sons, Inc. | 5-carboxy-1,4-dihydropyrimidine derivatives |
| GB8906168D0 (en) | 1989-03-17 | 1989-05-04 | Pfizer Ltd | Therapeutic agents |
| SE9702564D0 (sv) | 1997-07-02 | 1997-07-02 | Astra Ab | New compounds |
| SE9702563D0 (sv) | 1997-07-02 | 1997-07-02 | Astra Ab | Compounds |
| DE19817264A1 (de) | 1998-04-18 | 1999-10-21 | Bayer Ag | Neue Dihydropyrimidine |
| DE19817262A1 (de) | 1998-04-18 | 1999-10-21 | Bayer Ag | Neue 2-heterocyclisch substituierte Dihydropyrimidine |
| DE19817265A1 (de) | 1998-04-18 | 1999-10-21 | Bayer Ag | Verwendung von Dihydropyrimidinen als Arzneimittel und neue Stoffe |
| WO2000058302A1 (de) | 1999-03-25 | 2000-10-05 | Bayer Aktiengesellschaft | Dihydropyrimidine und ihre verwendung zur behandlung von hepatitis b |
| DE10012549A1 (de) | 2000-03-15 | 2001-09-20 | Bayer Ag | Arzneimittel gegen virale Erkrankungen |
| DE10012824A1 (de) | 2000-03-16 | 2001-09-20 | Bayer Ag | Arzneimittel gegen virale Erkrankungen |
| DE10012823A1 (de) | 2000-03-16 | 2001-09-20 | Bayer Ag | Arzneimittel gegen virale Erkrankungen |
| DE10013126A1 (de) | 2000-03-17 | 2001-09-20 | Bayer Ag | Arzneimittel gegen virale Erkrankungen |
| DE10013125A1 (de) | 2000-03-17 | 2001-09-20 | Bayer Ag | Arzneimittel gegen virale Erkrankungen |
| WO2005007124A2 (en) | 2003-07-23 | 2005-01-27 | Bristol-Myers Squibb Company | Substituted dihydropyrimidine inhibitors of calcium channel function |
| CN101104604B (zh) | 2006-07-10 | 2011-03-02 | 北京摩力克科技有限公司 | 光学纯二氢嘧啶类化合物及其用于制备治疗和预防病毒性疾病的药物的用途 |
| CN101104617B (zh) | 2006-07-10 | 2010-06-23 | 北京摩力克科技有限公司 | 二氢嘧啶类化合物及其用于制备治疗和预防病毒性疾病的药物的用途 |
| CN101225084A (zh) | 2007-01-16 | 2008-07-23 | 北京摩力克科技有限公司 | 二氢嘧啶类化合物及其用于制备治疗和预防病毒性疾病的药物的用途 |
| CA2691056C (en) * | 2007-06-18 | 2014-03-11 | Zhang, Zhongneng | Bromo-phenyl substituted thiazolyl dihydropyrimidines for treating and preventing hepatitis b infections |
| CN101328170B (zh) | 2007-06-18 | 2011-09-14 | 张中能 | 一种氟苯基-取代噻唑二氢嘧啶 |
| CN101328168B (zh) | 2007-06-18 | 2011-09-07 | 张中能 | 一种乙氧碳酰基-取代噻唑二氢嘧啶 |
| WO2008154819A1 (fr) | 2007-06-18 | 2008-12-24 | Zhang, Zhongneng | Thiazolyl-dihydropyrimidines à substitution carbéthoxy |
| CN101744823B (zh) | 2008-12-17 | 2013-06-19 | 广东东阳光药业有限公司 | 一种二氢嘧啶类化合物的固体分散体及其药用制剂 |
| WO2010069147A1 (zh) | 2008-12-17 | 2010-06-24 | 张中能 | 二氢嘧啶类化合物、其组合物及其应用 |
| CN101575318B (zh) | 2009-06-25 | 2012-02-08 | 中国人民解放军军事医学科学院毒物药物研究所 | 二氢嘧啶类化合物及其用于制备治疗和/或预防病毒性疾病的药物的用途 |
| US9487534B2 (en) | 2011-08-02 | 2016-11-08 | Scripps Research Institute, A Not-For-Profit Public Benefit Corporation Of California | Modulators of virus assembly as antiviral agents |
| KR102056665B1 (ko) | 2012-01-06 | 2019-12-17 | 얀센 사이언시즈 아일랜드 언리미티드 컴퍼니 | 4,4,-이치환-1,4-디하이드로피리미딘 및 b형 간염의 치료를 위한 약제로서 이의 용도 |
| US20130267517A1 (en) | 2012-03-31 | 2013-10-10 | Hoffmann-La Roche Inc. | Novel 4-methyl-dihydropyrimidines for the treatment and prophylaxis of hepatitis b virus infection |
| CA2876690C (en) | 2012-08-24 | 2020-06-09 | Sunshine Lake Pharma Co., Ltd. | Dihydropyrimidine compounds and their application in pharmaceuticals |
| CN103664897B (zh) | 2012-09-01 | 2018-04-03 | 广东东阳光药业有限公司 | 二氢嘧啶类化合物及其在药物中的应用 |
| CN103664925B (zh) | 2012-09-07 | 2018-01-23 | 广东东阳光药业有限公司 | 杂芳基取代的二氢嘧啶类化合物及其在药物中的应用 |
| HK1210152A1 (en) * | 2012-09-10 | 2016-04-15 | F. Hoffmann-La Roche Ag | 6-amino acid heteroaryldihydropyrimidines for the treatment and prophylaxis of hepatitis b virus infection |
| CN103664899B (zh) | 2012-09-11 | 2017-06-16 | 广东东阳光药业有限公司 | 杂芳基取代的二氢嘧啶类化合物及其在药物中的应用 |
| SG11201503475WA (en) | 2012-11-09 | 2015-05-28 | Univ Indiana Res & Tech Corp | Alternative uses for hbv assembly effectors |
| CN105188703A (zh) | 2013-03-20 | 2015-12-23 | 美国印第安纳大学研究和技术公司 | 荧光-hap：用于细胞中的hbv核的诊断性染色剂 |
| SG11201509463YA (en) | 2013-05-17 | 2015-12-30 | Hoffmann La Roche | 6-bridged heteroaryldihydropyrimidines for the treatment and prophylaxis of hepatitis b virus infection |
| RU2678990C1 (ru) | 2013-11-19 | 2019-02-05 | Саншайн Лейк Фарма Ко., Лтд. | Соединения дигидропиримидина и их применение в фармацевтических препаратах |
| CN104650069B (zh) | 2013-11-19 | 2019-04-19 | 广东东阳光药业有限公司 | 4-甲基二氢嘧啶类化合物及其在药物中的应用 |
| CN104650070B (zh) | 2013-11-25 | 2018-09-14 | 广东东阳光药业有限公司 | 二氢嘧啶类化合物及其在药物中的应用 |
| SG11201601813UA (en) * | 2013-11-27 | 2016-04-28 | Sunshine Lake Pharma Co Ltd | Processes for preparing dihydropyrimidine derivatives and intermediates thereof |
| PE20161338A1 (es) | 2014-03-07 | 2016-12-12 | Hoffmann La Roche | Nuevas heteroarildihidropirimidinas 6-fusionadas para el tratamiento y la profilaxis de la infeccion por virus de la hepatitis b |
| KR102428878B1 (ko) | 2014-05-30 | 2022-08-04 | 치루 파머수티컬 컴퍼니 리미티드 | Hbv억제제인 디히드로피리미도 축합환 유도체 |
-
2015
- 2015-03-27 RU RU2016138735A patent/RU2682672C2/ru active
- 2015-03-27 MY MYPI2016702906A patent/MY196243A/en unknown
- 2015-03-27 AU AU2015236982A patent/AU2015236982B2/en active Active
- 2015-03-27 CN CN201510141969.5A patent/CN104945395B/zh active Active
- 2015-03-27 MX MX2016012573A patent/MX2016012573A/es unknown
- 2015-03-27 EP EP15769748.3A patent/EP3122747B1/en active Active
- 2015-03-27 JP JP2016558407A patent/JP2017512789A/ja active Pending
- 2015-03-27 KR KR1020167029448A patent/KR20160133563A/ko not_active Withdrawn
- 2015-03-27 WO PCT/CN2015/075299 patent/WO2015144093A1/en not_active Ceased
- 2015-03-27 US US15/116,226 patent/US9771358B2/en active Active
- 2015-03-27 CA CA2938050A patent/CA2938050A1/en not_active Abandoned
- 2015-03-27 SG SG11201605896WA patent/SG11201605896WA/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| US9771358B2 (en) | 2017-09-26 |
| EP3122747B1 (en) | 2020-05-20 |
| SG11201605896WA (en) | 2016-08-30 |
| US20160347746A1 (en) | 2016-12-01 |
| WO2015144093A1 (en) | 2015-10-01 |
| AU2015236982A1 (en) | 2016-08-11 |
| KR20160133563A (ko) | 2016-11-22 |
| MY196243A (en) | 2023-03-24 |
| JP2017512789A (ja) | 2017-05-25 |
| CN104945395B (zh) | 2018-01-23 |
| RU2016138735A3 (enExample) | 2018-05-03 |
| EP3122747A1 (en) | 2017-02-01 |
| CN104945395A (zh) | 2015-09-30 |
| EP3122747A4 (en) | 2017-11-15 |
| RU2016138735A (ru) | 2018-05-03 |
| AU2015236982B2 (en) | 2017-12-14 |
| RU2682672C2 (ru) | 2019-03-20 |
| CA2938050A1 (en) | 2015-10-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MY196243A (en) | Dihydropyrimidine Compounds and Their Application In Pharmaceuticals | |
| MX2016006564A (es) | Compuestos dihidropirimidina y su aplicacion en productos farmaceuticos. | |
| MY182403A (en) | Dihydropyrimidine compounds and their application in pharmaceuticals | |
| MY194405A (en) | Dihydropyrimidine compounds and uses thereof in medicine | |
| PH12019500395A1 (en) | Amino-pyrrolopyrimidinone compounds and methods of use thereof | |
| MD20170016A2 (ro) | Compuşi aminopirimidinici ca inhibitori JAK | |
| PH12016501972B1 (en) | Bicyclic-fused heteroaryl or aryl compounds and their use as irak4 inhibitors | |
| NZ736665A (en) | Heterocyclic amides as kinase inhibitors | |
| GEP20186892B (en) | 2-amino-3, 5, 5-trifluoro-3, 4, 5, 6-tetrahydropyridines as bace1 inhibitors for treatment of alzheimer's disease | |
| MX391812B (es) | Agonista fxr derivado de esteroides. | |
| PH12016502081A1 (en) | Compounds for treating spinal muscular atrophy | |
| MX381994B (es) | Inhibidor de janus quinasa. | |
| SA515360469B1 (ar) | مركبات حلقية غير متجانسة لتثبيط إنزيم جلوتاميناز والطرق الخاصة باستخدامها | |
| MX2016006432A (es) | Tetrahidro-benzodiazepinonas. | |
| PH12018500061A1 (en) | Oxysterols and methods of use thereof | |
| MX2018005041A (es) | Compuestos para tratar la esclerosis lateral amiotrofica. | |
| MY194116A (en) | Pharmaceutical compounds | |
| TW201613864A (en) | Novel compounds | |
| MX377202B (es) | Derivado basado en 1,2-naftoquinona y metodo de preparacion del mismo. | |
| MX2016009794A (es) | Derivado de sulfonamida heterociclico y medicina que comprende el mismo. | |
| EA033446B1 (ru) | Гетероциклическое соединение для лечения дегенерации желтого пятна и/или болезни штаргардта | |
| MX2016011105A (es) | Inhibidores de monoacilglicerol aciltransferasa 2 (mgat2) de dihidropiridinona para usarse en el tratamiento de trastornos metabolicos. | |
| JO3372B1 (ar) | مشتقات 5-بنزيل إيزوكينولين لعلاج أمراض القلب والأوعية الدموية | |
| MX376029B (es) | Compuestos de isoindol. | |
| PH12018501709A1 (en) | Naphthridinedione derivatives |